Trials / Completed
CompletedNCT00061672
Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-510 - Thrombospondin-1 Mimetic |
Timeline
- Start date
- 2003-04-01
- First posted
- 2003-06-04
- Last updated
- 2007-08-15
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00061672. Inclusion in this directory is not an endorsement.